Calcineurin inhibitor dose-finding before kidney transplantation in HIV patients

Transplant International

Volumn 26, Issue 3, 2013, Pages 254-258

  Pulzer, Alina ^a   Seybold, Ulrich ^a   Schönermarck, Ulf ^a   Stangl, Manfred ^b   Habicht, Antje ^a   Bogner, Johannes R ^a   Franke, Jörg ^c   Fischereder, Michael ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Schwabing General Hospital   (Germany)

Author keywords

complications; immunosuppression; outcome; rejection; tacrolimus

Indexed keywords

ABACAVIR; CYCLOSPORIN A; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; SAQUINAVIR; TACROLIMUS; TENOFOVIR; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT REJECTION; HEART VENTRICLE TACHYCARDIA; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; CALCINEURIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GRAFT SURVIVAL; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SAFETY; PREOPERATIVE CARE; RISK ASSESSMENT; SAMPLING STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 84874029440     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12020     Document Type: Article

References (27)

1. Sugawara Y, Tamura S, Kokudo N,. Liver transplantation in HCV/HIV positive patients. World J Gastrointest Surg 2011; 3: 21.
2. Choi A, Scherzer R, Bacchetti P, et al,. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56: 872.
3. Maggi P, Bartolozzi D, Bonfanti P, et al,. Renal complications in HIV disease: between present and future. AIDS Rev 2012; 14: 37.
4. Trullas JC, Cofan F, Tuset M, et al,. Renal transplantation in HIV-infected patients: 2010 update. Kidney Int 2011; 79: 825.
5. Yoon SC, Hurst FP, Jindal RM, et al,. Trends in renal transplantation in patients with human immunodeficiency virus infection: an analysis of the United States renal data system. Transplantation 2011; 91: 864.
6. Lao CK, Gruta C, John MD,. A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians. J Natl Med Assoc 2011; 103: 518.
7. Elewa U, Sandri AM, Rizza SA, Fervenza FC,. Treatment of HIV-associated nephropathies. Nephron Clin Pract 2011; 118: c346; discussion c54.
8. Phair J, Palella F,. Renal disease in HIV-infected individuals. Curr Opin HIV AIDS 2011; 6: 285.
9. Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD,. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006; 42: 1488.
10. Landin L, Rodriguez-Perez JC, Garcia-Bello MA, et al,. Kidney transplants in HIV-positive recipients under HAART. A comprehensive review and meta-analysis of 12 series. Nephrol Dial Transplant 2010; 25: 3106.
11. Martina MN, Cofan F, Suarez A, et al,. Kidney transplantation and waiting list for renal transplantation for human immunodeficiency virus patients. Transplant Proc 2010; 43: 2179.
12. Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL,. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004; 15: 1633.
13. Miro JM, Ricart MJ, Trullas JC, et al,. Simultaneous pancreas-kidney transplantation in HIV-infected patients: a case report and literature review. Transplant Proc 2010; 42: 3887.
14. Barcan L, Gadano A, Casetti I, Villamil F,. Organ transplants in HIV infected patients. Update and recommendations. Medicina (B Aires) 2011; 71: 59.
15. Roefs A, van der Ende M, J IJ, Weimar W, van Gelder T,. Long-term survival after kidney transplantation in an HIV-positive patient. Clin Transplant 2009; 23: 278.
16. Bossini N, Sandrini S, Valerio F,. Kidney transplant in patients with HIV infection. G Ital Nefrol 2012; 29: 404.
17. Jung O, Geiger H,. Nierenerkrankungen bei HIV-Infektion unter HAART. Der Nephrologe 2008; 3: 22.
18. Jain AB, Venkataramanan R, Eghtesad B, et al,. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003; 9: 954.
19. Guaraldi G, Cocchi S, Motta A, et al,. Differential dose adjustments of immunosuppressants after resuming boosted versus unboosted HIV-protease inhibitors postliver transplant. Am J Transplant 2009; 9: 2429.
20. Gruber SA, Doshi MD, Cincotta E, et al,. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation 2008; 86: 269.
21. Trullas JC, Mocroft A, Cofan F, et al,. Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr 2010; 55: 582.
22. Bickel M, Anadol E, Vogel M, et al,. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother 2010; 65: 999.
23. Ikezoe T, Hisatake Y, Takeuchi T, et al,. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004; 64: 7426.
24. Schiff J, Cole E, Cantarovich M,. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007; 2: 374.
25. Jain AK, Venkataramanan R, Shapiro R, et al,. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8: 841.
26. Jain AK, Venkataramanan R, Shapiro R, et al,. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. Transplant Proc 2002; 34: 1540.
27. Waki K, Sugawara Y,. Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572). Biosci Trends 2011; 5: 189.